General characteristics and clinical practices of Chinese patients with non-alcoholic fatty liver disease.
- Author:
Min-de ZENG
1
;
Bing-yuan WANG
;
Cheng-wei CHEN
;
Rui-hua SHI
;
You-ming LI
;
Xiao-hua HOU
;
Shi-ying XUAN
;
Xiao-ping ZOU
;
Yu-yuan LI
;
Jia-ji JIANG
;
Zhen-ya SONG
;
Jian-gao FANG
;
Yi-min MAO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Asian Continental Ancestry Group; China; epidemiology; Fatty Liver; diagnosis; epidemiology; therapy; Female; Humans; Male; Metabolic Syndrome; epidemiology; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Waist Circumference
- From: Chinese Journal of Hepatology 2011;19(5):362-366
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the characteristics and daily treatment compliance of non-alcoholic fatty liver disease (NAFLD) patients in China.
METHODSNAFLD adult patients from 21 clinics of 12 cities in China were enrolled in this registry. Physical examination such as demographic characteristics (height, weight, waist circumference measurement), blood pressure and clinical laboratory and ultrasonographic examination of liver were undertaken. Daily practice including life style and medication were recorded and assessed in accordance with 2006 Chinese NAFLD treatment guidelines.
RESULTSA total of 1656 patients were enrolled (1146 male and 510 female), mean of 45.8 ± 12.6 years old, mean duration of NAFLD history was (47.2 ± 47.7) months. 44.9% of NAFLD were suffering from metabolic syndromes. Patients with central obesity have higher incidence of hypertension and lower level of high-density lipoprotein cholesterol (HDL-C) than those without central obesity, P < 0.05. Body mass index (BMI), waist circumference, triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in ALT abnormal group were higher than those in ALT normal group (P < 0.05), HDL-C was lower in ALT abnormal group (P < 0.05). Significant differences existed between the BMI, female waist circumference, TG, fast insulin, HOMA index, ALT, AST and HDL-C among subgroups with mild, moderate and severe steatosis. Majority of the patients did not follow recommendations of NAFLD treatment guidelines. Among targeted population only 15.3% of patients used insulin sensitizers and 23.8% took lipid lowering medicine according to the guideline.
CONCLUSIONData indicated that nearly half of NAFLD patients co-morbid with metabolic disorders. Therapy compliance was unsatisfactory and the gap between current practice and Chinese NAFLD treatment guidelines was not optimal.